Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
"Novo Nordisk continues to explore semaglutide across metabolic and cardiovascular health, including MASH, a condition with limited treatment options for patients and healthcare professionals," said Anna Windle, PhD, senior vice president of clinical development, medical and regulatory affairs at Novo Nordisk, maker of Ozempic and Wegovy, in a press release provided to Fox News Digital
Abbreviations BMI: Body mass index DPP-4is: Dipeptidyl peptidase-4 inhibitors GLP-1 RAs: Glucagon-like peptide-1 receptor agonists HbA1c: Hemoglobin Alc ICERs: Incremental cost-effectiveness ratios PSA: Probabilistic sensitivity analyses QALYs: Quality-adjusted life years SBP: Systolic blood pressure SMPA: Sunshine Medical Procurement All-In-One UKPDS: United Kingdom Prospective Diabetes Studies References International Diabetes Federation
Dont let frustration hold you back any longer
Compelling preclinical rationale, early adopter enthusiasm, and a safety evidence base that wouldn't survive FDA scrutiny
US$ 28.64
US$ 21.74
US$ 20.97
US$ 28.52
US$ 28.61
US$ 20.04
US$ 26.93
